First in class, best in class or a wild card: who will dominate the anti-obesity medication market?
Publication: Journal of Comparative Effectiveness Research
Formats available
You can view the full content in the following formats:
References
1.
World Obesity Day Atlases. Obesity Atlas 2023. World Obesity Federation Global Obesity Observatory. Available from: https://data.worldobesity.org/publications/?cat=19
2.
Mohajan D, Mohajan HK. Obesity and its related diseases: a new escalating alarming in global health. J. Innov. Med. Res. 2, 12–23 (2023).
3.
Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int. J. Obes. 45, 1249–1258 (2021).
4.
Evans M, de Courcy J, de Laguiche E et al. Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey. Int. J. Obes. 47, 750–757 (2023).
5.
WHO MiNDbank - Sozialgesetzbuch (SGB) Fünftes Buch (V) Gesetzliche Krankenversicherung (Social Code (SGB) Book Five (V) Statutory Health Insurance). Available from: https://extranet.who.int/mindbank/item/2266
6.
Obesity drugs are a potential US$100 billion opportunity by 2030, say Goldman Sachs analysts, Companies & Markets - THE BUSINESS TIMES. Available from: https://www.businesstimes.com.sg/companies-markets/obesity-drugs-are-potential-us100-billion-opportunity-2030-say-goldman-sachs
7.
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements | Eli Lilly and Company. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2023-financial-results-highlights
8.
Liu A. After splashing $1B, Roche returns Gavreto to Blueprint. Available from: https://www.fiercepharma.com/pharma/after-splashing-1b-roche-returns-lagging-cancer-drug-gavreto-blueprint (2023).
9.
The fall of the world's best-selling drug. Available from: https://www.ft.com/content/d0f7af5c-d7e6-11de-b578-00144feabdc0
10.
Keytruda vs. Opdivo: No Contest. Available from: https://www.science.org/content/blog-post/keytruda-vs-opdivo-no-contest
11.
Irfan H. Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT Trial. Curr. Probl. Cardiol. 49, 102060 (2024).
12.
FDA. FDA Approves New Medication for Chronic Weight Management. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management (2023).
13.
Drugs@FDA. FDA-Approved Drugs. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
14.
Drugs@FDA. FDA-Approved Drugs. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321
15.
Drugs@FDA. FDA-Approved Drugs. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
16.
Drugs@FDA. FDA-Approved Drugs. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
17.
Kalapala R. Efficacy of Oral Semaglutide in Overweight or Obesity: Randomized Controlled Trial (OSO Study - Oral Semaglutide for Obesity). (2022). Available from: https://clinicaltrials.gov/study/NCT05442450
18.
Novo Nordisk A/S. Efficacy and Safety of Cagrilintide s.c. 2.4 Mg in Combination With Semaglutide s.c. 2.4 Mg (CagriSema s.c. 2.4 Mg/2.4 Mg) Once-Weekly in Participants With Overweight or Obesity and Type 2 Diabetes. (2024).Available from: https://clinicaltrials.gov/study/NCT05394519
19.
Hangzhou Sciwind Biosciences Co., Ltd. A Phase III, Multi-Center, Randomized, Double-Blind and Placebo-Controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER). (2023).Available from: https://clinicaltrials.gov/study/NCT05813795
20.
Eli Lilly and Company. A Phase III, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). (2023).Available from: https://clinicaltrials.gov/study/NCT05869903
21.
Boehringer Ingelheim. A Phase III, Randomised, Double-Blind, Parallel-Group, 76-Week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus. (2024).Available from: https://clinicaltrials.gov/study/NCT06066528
22.
Eli Lilly and Company. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1). (2023).Available from: https://clinicaltrials.gov/study/NCT05929066
23.
Priyan V. Innovent doses first subject in phase III trial of obesity drug. Clinical Trials Arena (2024).Available from: https://www.clinicaltrialsarena.com/news/innovent-obesity-drug-trial/
24.
Eli Lilly and Company. A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women. (2023).Available from: https://clinicaltrials.gov/study/NCT05616013
25.
Inc, A. Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide. GlobeNewswire News Room (2023).Available from: https://www.globenewswire.com/news-release/2023/11/30/2788970/0/en/Altimmune-Announces-Positive-Topline-Results-from-MOMENTUM-48-Week-Phase-2-Obesity-Trial-of-Pemvidutide.html
26.
VK2735. Viking Therapeutics Available from: https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2735/
27.
Amgen. A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. (2024).Available from: https://clinicaltrials.gov/study/NCT05669599
28.
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update | Structure Therapeutics. Available from: https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-positive-results-phase-1b/
29.
Rivus Pharmaceuticals. Rivus Available from: https://www.rivuspharma.com/
30.
Carmot Therapeutics, Inc. A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus. (2022).Available from: https://clinicaltrials.gov/study/NCT04838405
31.
Our Pipeline. Carmot Therapeutics. Drug Discovery and Development. Carmot Therapeutics Available from: https://carmot.us/pipeline/
32.
New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery | Pfizer. Available from: https://www.pfizer.com/science/drug-product-pipeline
33.
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity. Available from: https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html (2023).
34.
R&D pipeline. Novo Nordisk. Available from: https://www.novonordisk.com/content/nncorp/global/en/science-and-technology/r-d-pipeline.html
35.
Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12, 219–230 (2011).
36.
Wilding JPH, Batterham RL, Calanna S et al. STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384(11), 989–1002 (2021).
37.
Jastreboff AM, Aronne LJ, Ahmad NN et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387(3), 205–216 (2022).
38.
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5). Available from: https://trials.lilly.com/en-US/trial/399775
39.
Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553–1564 (2022).
40.
Aronne LJ, Sattar N, Horn DB et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 Randomized Clinical Trial. JAMA 331, 38–48 (2024).
41.
Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? JAMA 317, 1017–1018 (2017).
42.
Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
43.
Bril F. Semaglutide in NASH-related cirrhosis: too late to the party? Lancet Gastroenterol. Hepatol. 8, 494–495 (2023).
44.
Boye K, Ross M, Mody R, Konig M, Gelhorn H. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study. Diabetes Obes. Metab. 23, 508–519 (2021).
45.
Choi J. Medicare to cover obesity drugs, but not for weight loss, The Hill (2024) Available from: https://thehill.com/policy/healthcare/4548098-medicare-obesity-drugs-weight-loss/
46.
Blankenship K. ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe | Fierce Pharma Available from: https://www.fiercepharma.com/pharma/esc-pfizer-bms-eliquis-adds-to-lead-competitor-topping-french-real-world-data (2019).
Information & Authors
Information
Published In
Copyright
© 2024 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 22 March 2024
Accepted: 3 May 2024
Published online: 29 May 2024
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
First in class, best in class or a wild card: who will dominate the anti-obesity medication market?. (2024) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0044
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Brian E. Roe, De gustibus est disputandum : The role of agricultural and applied economists in an era of behavior change initiatives and endogenous preferences , American Journal of Agricultural Economics, 10.1002/ajae.70049, 108, 2, (429-442), (2026).
- Livio Garattini, Antonino Mazzone, Obesity in Europe: Less impact on chronic diseases thanks to internists?, European Journal of Internal Medicine, 10.1016/j.ejim.2025.01.011, 136, (138-139), (2025).
- Livio Garattini, Giovanni Fattore, Obesity epidemic in European countries: from an unaddressed risk factor to a medicalized disease?, The European Journal of Health Economics, 10.1007/s10198-024-01752-5, 26, 1, (1-5), (2024).
- Paul Arora, Sreeram V Ramagopalan, R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17, Journal of Comparative Effectiveness Research, 10.57264/cer-2024-0212, 14, 1, (2024).